EZH2 and acute myeloid leukemia: There is evidence suggesting the combination of EZH2 inhibitors (i.e., S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep)) and Panobinostat (histone deacetylase inhibitor) results in apoptosis of AML progenitor cells by inhibition of H3K27me3 along with deacetylation of histones [96].